

NEW YORK, NY LOS ANGELES, CA PALM BEACH, FL



ChineseInvestors.com Inc. Ticker: (OTCQB: CIIX)

Corporate Profile as of January 22, 2017

ChineseInvestors.com, Inc., (CIIX), headquartered in Los Angeles, with offices in New York City and Shanghai China, is a firm that engages in providing a wide range of products and services for the global Chinese population. Web-based real-time financial information is provided via the Company's dynamic financial website, www.Chinesefn.com, caters to Chinese investors by offering timely market information of US publicly traded stocks and foreign currencies with free quotes, charts, market news, and links to investment research. The Company offers various products beyond the website information such as subscription services, real-time financial analysis. It tracks US stock market quotations, and provides access to sample investment portfolios for educational simulation, as well as real-time trading demonstrations. The Company also offers a wide range of investor relations services to publicly-traded companies in the US and China. The Company has profited from earning and holding shares in several public companies through its consulting and advisory services over the past few years. The Company is changing its focus from being a premier investment Internet information provider, expanding into retail and online sales of CBD products, and consulting for medical marijuana and derivative medical marijuana markets. The Company's goal is to up-list onto the NASDAQ or NYSE Markets sometime later this year when qualified.

Most recently, ChineseInvestors.com has begun implementing its plans for a new website, mobile app and online distribution of CBD oils for the booming global Medical Marijuana industry. While marijuana use in China is illegal, cannabis based oils (cannabidiol) including Hemp based CBD's are legal, thus opening a potential market of over one Billion people for the Company. Hemp CBD is a non-toxic and non-addictive natural concentrate extracted from the Cannabis plant. According to major research studies and a CNN documentary, CBDs have been shown to be effective in treating Epilepsy, Alzheimer's disease, cirrhosis of the liver, and can provide relief from hangovers, anxiety and stress. According to the Chinese Overseas Medical Advisory Service Center, China has nearly 10 million Epilepsy patients, with Epilepsy being one of the major focuses for medical procedures or products seeking to cure. Epilepsy can be cured through surgical treatment, although there is a known high-risk factor involved in this procedure. As a result, most Chinese professionals and patients seek conservative herbal treatment methods and are beginning to seek alternativess based on Western Medicine. New findings are showing that CBD oils are offering potential for treating Epilepsy thus CBD oils are fast becoming an option globally. According to a recent article in Bloomberg Markets, the US, the Medical Marijuana industry may grow to \$50 Billion in the next decade with expansion 8x its current size. (Source: Jennifer Kaplan; Bloomberg Markets, 2016) This rapid growth and the positioning that CIIX has with the Chinese markets positions the Company for gaining revenue and market share in this booming industry.

CIIX recently announced plans to launch the world's first Cannabidiol (CBD) Health products online store in the Chinese Language by the end of January 2017. The Company is working on wholesale agreements with well-known CBD oil brands that will allow CBD oils to be marketed and sold online via the www.ChineseCBDoil.com website and at retail in-store sales in Shanghai, China.

Mr. Wang, the CEO stated, "According to The CBD Report published by The Hemp Business Journal, Cannabidiol is one of the fastest-growing market categories in the U.S. hemp and legal marijuana industries. In 2015, the CBD industry grew from a nearly invisible market a few years ago to \$202 million in consumer-sales, and it is further expected to grow to \$2.1 billion in consumer sales by 2020. We are very excited that CIIX is launching the world's first CBD online store focused on providing CBD health products for Chinese-speaking customers and making it possible for them to order various types of CBD products through www.chinesecbdoil.com."

All figures beloww ar	e quoted in US	Dollars and in	Thousands								
Income Statement	FY 5/31/16	FY 5/31/15	thru 8/31/16	Balance Sheet	FY 5/31/16	FY 5/31/15	thru 8/31/16	Cash Flow Statement	FY 5/31/16	FY 5/31/15	thru 8/31/16
Revenue	903	2,442	341	Cash	197	498	313	Operating Cash Flow	(1,584)	(1,380)	(720)
Operating Loss	(2,923)	(483)	(914)	Total Assets	2,882	2,264	1,709	Investing Cash Flow	(21)	4	873
Net Loss	(2,026)	(2,327)	(172)	Total Liabilities	1,288	667	1,634	Financing Cash Flow	1,304	1,445	(38)
Loss Per Share	(0.29)	(0.51)	(0.02)	Total Shareholder's Equity	1,593	1,596	75	Cash at end of period	197	498	313
CITIC Doc 1/5 - P12 ge=3 ^{max} - Vol Loss - -	ui		r Price C		2.00 1.79 1.29 1.29 1.29 0.79 0.90 0.90 0.90 0.00			2: CIIX 1 Mont		OBIgOher	1 - 200-17 1 - 10 1 - 10 0

Sector: Technology / Media Industry: Internet Info Providers Website: www.Chinesefn.com

Key Statistics

y otherotico						
Price 1/20/2017	1.75					
52 Week High	1.95					
52 Week Low	0.30					
Avg. Vol (30day)	160,453					
Market Cap (Interday)	13.41					
Price/Sales (TTM)	12.44					
Common Shares Outstanding (M)	7.66					
Preferred Stock Outstanding (M)	3.44					
Float	6.88					
EPS(TTM)	-0.21					
Beta	0.37					
QTR Revenue Growth (yoy)	105%					
Source: Yahoo Finance / Google Finance						

Recent 2016 Highlights

- January 19, 2017, The Company filed with the SEC, a Form D announcing plans to issue up to \$5 Million dollars in an equity offering to accredited investors.
- January 12, 2017, The Company announced its new headquarters in Shanghai China, for the worlds first CBD oil health products online store; www.Chinesecbdoil.com presented in the Chinese Mandarin language. The Company plans to set up a wholly owned subsidiary in the Shanghai free-trade zone which will focus on a global wholesale and retail business of supplying CBD oil products.
- On December. 14, 2016, The Company announced a joint development with a manufacturing distributor of CBD oil products enabling the Company to wholesale and retail CBD products to the Asian health products market via online and in-store sales.
- On November. 21, 2016, CIIX announced that it has appointed Kevin Ge as its Chief Technology Officer. Mr. Ge will be overseeing the IT and development of the new website and mobile app.
- October 15, 2016, The Company announced quarterly revenues of \$341,000 dollars which is an increase of 105% from last years \$166,000 in the same quarter. Loss per share declined from .09 cents per share to .02 cents per share.

Corporate Contact Information

ChineseInvestors.com Inc.

Warren Wang, CEO 14 Wall Street, 20th Floor New York, NY 10005 Email: warrenwang@chinesefn.com www.Chinesefn.com www.ChineseCBDoil.com

The information presented herein is not to be construed as an offer to sell, nor a solicitation of an offer to purchase, any securities. This corporate profile is not a research report, but a compilation of information available to the public, which has been furnished by the featured company or gathered from other sources, in each case without independent verification, and no representations are made as to he accuracy or validity thereof. The information may include certain forward-looking statements within the meaning of Section 21E of the SEC Act of 1934, which may be affected by unforeseen circumstances or certain risks. Any investment in securities contains inherent risks and should only be done after consulting an investment professional. The featured company will pay a fee of \$6000 in cash to Alan Stone & Company LLC for preparation and distribution of this profile, including other potential fees associated with various consulting and investor relation services. For complete disclaimer information, the readers are hereby referred to the Disclaimer Page at the www.WallStreetResearch.org website.

Copyright © January 2017 Alan Stone & Company LLC and WallStreet Research[™], All Rights Reserved